LUGANO, Switzerland — The advent of the Pola-R-CHP (polatuzumab plus R-CHOP) regimen has shaken up the long-held standard of R-CHOP in the treatment of diffuse large B-cell lymphoma (DLBCL) and should ...
BOSTON--(BUSINESS WIRE)--Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel ...
Higher rates of adverse events offset the positive survival results in an area of great unmet need. For decades, the standard ...
OLYMPIA-3 trial at ASCO 2026 shows odronextamab plus CHOP in higher-risk B-cell lymphoma delivers strong MRD-negative CRs ...
Diffuse large B-cell lymphoma (DLBCL) stage 4 is an advanced cancer. Despite its aggressive nature, DLBCL usually responds well to treatment, and new therapies are being developed to help improve ...
Traits of noncancerous cells in diffuse large B-cell lymphoma (DLBCL) tumors appear to offer insight into which patients will benefit the most from chimeric antigen receptor (CAR) T-cell therapy, ...
Around 30% to 40% of people with diffuse large B-cell lymphoma (DLBCL) experience a relapse after remission, and 83% of those who relapse have symptoms. Relapse symptoms can be the same as those that ...
Researchers identified nearly 50,000 patients diagnosed with DLBCL over a 15-year period to measure the impact of SES on 5-year overall survival (OS). Patients living in low SES regions had ...
About 30 percent of all non-Hodgkin lymphoma diagnoses in the United States are DLBCL. Although it is an aggressive cancer that can spread quickly, it is treatable. These can be symptoms of many ...
—This large, population-based study of patients with PP-DLBCL assessed prognostic factors and confirmed that certain common therapeutic interventions can modify disease progression. Being age 65 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results